β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma - Wikidata - awgldk - TriplyDB

β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma

β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma

http://www.wikidata.org/entity/Q24564890

about

β1 Integrins as Therapeutic Targets to Disrupt Hallmarks of Cancer β1 and β4 integrins: from breast development to clinical practice Computational identification of epigenetically regulated lncRNAs and their associated genes based on integrating genomic data.Identification of hub genes and regulatory factors of glioblastoma multiforme subgroups by RNA-seq data analysis Macrophage migration inhibitory factor downregulation: a novel mechanism of resistance to anti-angiogenic therapy.The Ketogenic Diet Alters the Hypoxic Response and Affects Expression of Proteins Associated with Angiogenesis, Invasive Potential and Vascular Permeability in a Mouse Glioma Model Mesothelial cells promote early ovarian cancer metastasis through fibronectin secretion.Mechanisms of glioma formation: iterative perivascular glioma growth and invasion leads to tumor progression, VEGF-independent vascularization, and resistance to antiangiogenic therapy.Bevacizumab treatment induces metabolic adaptation toward anaerobic metabolism in glioblastomas The future of high-grade glioma: Where we are and where are we going.Expression of galectin-1 in carcinoma-associated fibroblasts promotes gastric cancer cell invasion through upregulation of integrin β1.Two of Them Do It Better: Novel Serum Biomarkers Improve Autoimmune Hepatitis Diagnosis.mPGES-1 in prostate cancer controls stemness and amplifies epidermal growth factor receptor-driven oncogenicity.Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer.Macrolide analog F806 suppresses esophageal squamous cell carcinoma (ESCC) by blocking β1 integrin activation.STAT3 Blockade Inhibits Radiation-Induced Malignant Progression in Glioma.Talin1 targeting potentiates anti-angiogenic therapy by attenuating invasion and stem-like features of glioblastoma multiforme.Inhibition of integrin β1 decreases the malignancy of ovarian cancer cells and potentiates anticancer therapy via the FAK/STAT1 signaling pathway.Coordination of self-renewal in glioblastoma by integration of adhesion and microRNA signaling.Bevacizumab for glioblastoma: current indications, surgical implications, and future directions Prognostic value of β1 integrin expression in colorectal liver metastases Suppression of Eosinophil Integrins Prevents Remodeling of Airway Smooth Muscle in Asthma.GLUT3 upregulation promotes metabolic reprogramming associated with antiangiogenic therapy resistance.Integrin modulators: a patent review.Resistance to antiangiogenic therapy.Current evidence of temozolomide and bevacizumab in treatment of gliomas.Molecularly targeted therapies for recurrent glioblastoma: current and future targets.Recent advance in molecular angiogenesis in glioblastoma: the challenge and hope for anti-angiogenic therapy.Fibronectin: How Its Aberrant Expression in Tumors May Improve Therapeutic Targeting Identification of Bone-Derived Factors Conferring De Novo Therapeutic Resistance in Metastatic Prostate Cancer.Molecular Targeting of Integrins and Integrin-Associated Signaling Networks in Radiation Oncology.Epidermal growth factor-like module containing mucin-like hormone receptor 2 expression in gliomas.Induction of proline-rich tyrosine kinase 2 activation-mediated C6 glioma cell invasion after anti-vascular endothelial growth factor therapy.Hypoxia-Mediated Mechanisms Associated with Antiangiogenic Treatment Resistance in Glioblastomas.Glioblastoma in natalizumab-treated multiple sclerosis patients.The Microvascular Gap Junction Channel: A Route to Deliver MicroRNAs for Neurological Disease Treatment Adhesion- and stress-related adaptation of glioma radiochemoresistance is circumvented by β1 integrin/JNK co-targeting.Targeting the Cohesive Cluster Phenotype in Chordoma via β1 Integrin Increases Ionizing Radiation Efficacy.Neuropilin-1 modulates TGFβ signaling to drive glioblastoma growth and recurrence after anti-angiogenic therapy.Interest of integrins targeting in glioblastoma according to tumor heterogeneity and cancer stem cell paradigm: an update.

P2860

Q26774789-2B17B037-FCC0-4344-9183-8C42227E5B67 Q27000311-6CE4A43A-7873-4B40-948C-A65B9FBD5F44 Q30885763-65774B5B-C3B4-47F6-BC62-F787FAC0FBAD Q31125309-2560B0DD-E207-4CD8-BCF8-591F219B12E0 Q33853991-285B2BB8-D330-47C6-BF82-3B80C07A4C6C Q34044274-791986BE-7B38-418E-8F12-FAEE9B5CC376 Q34311697-54A0F3DB-4A25-40D2-B855-F55F7D2EFAD4 Q34347733-DC3A8E14-B54A-4456-B97A-61757EF42F8F Q34807753-49F166E5-794A-4582-A19B-743C55E82F31 Q35114090-3E503CF6-2BC5-4111-AAC5-99DAB1EAC8D4 Q35713332-3965EB36-A315-40AE-B888-1638BFD3CE01 Q35777077-9DBDE2E7-676F-4F2C-84C6-C82C46145116 Q35921941-5E93D407-C97B-4212-917F-B2306BF713F3 Q36070842-5FA69683-7759-4DDF-B61E-29D671E705E6 Q36140675-E8B6E73F-327A-4931-843E-7D6757186ED1 Q36172612-50313A7A-69E9-4C84-B83C-46241D8716F7 Q36413742-BE5DEEBE-6FD4-4ACF-B301-72C6D40F7F46 Q36592509-F492E143-AA67-40F4-A146-46C6F4131BC8 Q36785112-604F1F90-96A6-4694-984B-36AC2955F2D3 Q36822207-2B9723FE-A2CA-4B1A-8923-8F0D87708CF0 Q37452274-32AB2358-AD7A-4997-9FD2-43389F0C79DC Q37570406-BD29552E-1B49-49DA-ACE4-4EE5EA44C28F Q37599547-CCDC43B8-B561-4717-AB24-F0D99B2F89F1 Q38139612-863DE74B-EF74-480A-8779-DAE47E8F4F49 Q38197943-93A7A70F-4C61-4C96-95E5-50CD6BCE5074 Q38230650-7F9B1095-7218-4702-A180-D5A742B0CC03 Q38272728-2BDE1D51-FC7C-4146-B643-FA03BC2B4382 Q38599484-2739F717-A9DD-4EAB-9418-E061AE929570 Q38736395-01B62F1A-2855-46F0-A44B-1AEF661688DB Q38822335-8B2EF533-F53C-41C5-A17F-6032061936D3 Q38869424-A9D17933-128C-457B-8F37-EDC7C2B3AF60 Q38958545-7A6EBBC6-513B-4A1D-8729-30135DE49722 Q38989530-1FBD83CC-5E4B-44B1-B333-0CE17AD521FC Q39174318-762619D1-F507-4A95-90DD-DB0ECD223F3B Q40128064-9546BF99-375E-4E2E-BAF1-FB1D06CBAFAC Q41243197-85CC36FE-9875-4379-9093-036ECD9DB7ED Q41472395-D00E33B4-35F1-41A3-A964-BB6CFC8E6197 Q41989354-3E88DA7E-9290-487D-AE45-D60600AA824C Q42362586-31124EA0-0C8C-42CD-90C6-7A1C6C9E08C6 Q44411444-0553FD91-061B-4DFC-930F-347527D5FC9F

P2860

β1 integrin targeting potentiates antiangiogenic therapy and inhibits the growth of bevacizumab-resistant glioblastoma

http://www.wikidata.org/entity/Q24564890

description

2013 nî lūn-bûn

@nan

2013 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի մայիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

β1 integrin targeting potentia ...... cizumab-resistant glioblastoma

@ast

β1 integrin targeting potentia ...... cizumab-resistant glioblastoma

@en

β1 integrin targeting potentia ...... cizumab-resistant glioblastoma

@nl

type

label

β1 integrin targeting potentia ...... cizumab-resistant glioblastoma

@ast

β1 integrin targeting potentia ...... cizumab-resistant glioblastoma

@en

β1 integrin targeting potentia ...... cizumab-resistant glioblastoma

@nl

prefLabel

β1 integrin targeting potentia ...... cizumab-resistant glioblastoma

@ast

β1 integrin targeting potentia ...... cizumab-resistant glioblastoma

@en

β1 integrin targeting potentia ...... cizumab-resistant glioblastoma

@nl

P1433

Q24564890-1E00DD6B-DF2A-4DA4-A1BD-C15F0ED8D1A6

P1476

Q24564890-6ABF2D31-7961-42B2-A38A-59FBAFEE3CEE

P2093

Q24564890-3F47D601-5408-4E47-B4C9-5A1FB32B6F85

Q24564890-451597CF-956D-4942-9B46-E7421B603583

Q24564890-921E53BD-FA70-40C7-8C0E-C4CF246AD474

Q24564890-CC36CC83-EBC9-49F5-B24A-D4D18AD2A607

Q24564890-EE8FE820-0D30-410E-917D-4F6C83CBCD1E

P2860

Q24564890-00857672-EE9B-4FC2-9DFC-41A78B48D446

Q24564890-01A1657E-A60E-45CC-9D26-2CC1F4B02A7B

Q24564890-07E0A029-3E25-4CEA-BC55-951F21A0880D

Q24564890-09B22712-40B3-46D2-A73B-892C128A6E65

Q24564890-0E20DA1B-21F1-49B2-A2A9-4F6E93595385

Q24564890-1280B8B2-D60D-4161-B4E4-0AAF5AA95C5C

Q24564890-130AC34B-9F34-4610-A1BA-BB4BA68DDE93

Q24564890-1A74FBE2-AC01-4CC2-B7D3-07AF8F17C373

Q24564890-227CFC03-3BA9-4AA7-8298-19C88970FB63

Q24564890-2477C1B6-4850-4891-A77E-CACEF5BF2D8C

P304

Q24564890-87882C5A-D307-4553-93BA-F2256C3EDBF2

P31

Q24564890-9505BF44-92CB-46C9-A2A1-4D86900D3FE2

P3181

Q24564890-B2E90FF8-209F-4D6B-BDAE-4A27DA04AA7F

P356

Q24564890-306FF7B5-67E3-422B-87D1-C07E89421FA5

P407

Q24564890-13D766C9-60A1-47CC-B726-35EBDD387D56

P433

Q24564890-E4659748-9C0F-47C7-ADFC-02AC4CC50CB6

P478

Q24564890-8BA279F0-4E7A-486D-932B-C8EBF7A1AE62

P577

Q24564890-95746B47-ED5B-4F20-A7BD-AE54A0DBC3DB

P698

Q24564890-3EEDC4DF-73C6-4966-AD6C-3D04F396207E

P921

Q24564890-F1E59B3A-285E-4808-8F8D-E917F1EFF3C4

P932

Q24564890-E9448974-3D74-48F6-8EFC-B70EA1B0940C

P3181

P356

0008-5472.CAN-13-0011

P1433

Cancer Research

P1476

β1 integrin targeting potentia ...... cizumab-resistant glioblastoma

@en

P2093

Arman Jahangiri

http://www.w3.org/2001/XMLSchema#string

Catherine C Park

http://www.w3.org/2001/XMLSchema#string

Manish K Aghi

http://www.w3.org/2001/XMLSchema#string

Michael DeLay

http://www.w3.org/2001/XMLSchema#string

W Shawn Carbonell

http://www.w3.org/2001/XMLSchema#string

P2860

Changes in laminin isoforms associated with brain tumor invasion and angiogenesis

Modes of resistance to anti-angiogenic therapy

Glioblastoma angiogenesis and tumor cell invasiveness are differentially regulated by β8 integrin

The vascular basement membrane as "soil" in brain metastasis

Alpha v beta 1 is a receptor for vitronectin and fibrinogen, and acts with alpha 5 beta 1 to mediate spreading on fibronectin

Integrins in cancer: biological implications and therapeutic opportunities

In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro

Migration of perilesional microglia after focal brain injury and modulation by CC chemokine receptor 5: an in situ time-lapse confocal imaging study.

Promising survival for patients with newly diagnosed glioblastoma multiforme treated with concomitant radiation plus temozolomide followed by adjuvant temozolomide.

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

P304

3145-54

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

169543

http://www.w3.org/2001/XMLSchema#string

P356

10.1158/0008-5472.CAN-13-0011

http://www.w3.org/2001/XMLSchema#string

P407

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

73

http://www.w3.org/2001/XMLSchema#string

P577

2013-05-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23644530

http://www.w3.org/2001/XMLSchema#string

P921

P932

4040366

http://www.w3.org/2001/XMLSchema#string